Z-Ile-Leu-aldehyde (Synonyms: Z-IL-CHO; GSI-XII; γ-Secretase inhibitor XII) |
Catalog No.GC15896 |
potent gamma-Secretase inhibitor
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 161710-10-7
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Z-Ile-Leu-aldehyde (gamma-Secretase inhibitor XII /GSI XII, Z-IL-CHO) is a potent gamma-Secretase inhibitor and Notch signaling inhibitor.
Notch signaling impinges on many cellular processes, including cell proliferation, differentiation, apoptosis, and maintenance of stem cells. It is also involved in many developmental systems, including neurogenesis, angiogenesis, hematopoiesis, and myogenesis. Deregulation of Notch signaling leads to developmental syndromes and cancer [3]. In order to transmit a signal, Notch receptors undergo a series of proteolytic cleavages after binding their cognate ligands of the Delta-like and Jagged family. γ-Secretase is a large protease complex that cleaves the membrane-bound form of Notch and releases the intracellular domain of the Notch receptor. This step in Notch signaling is pivotal in the activation of this signaling cascade [1] [2].
In vitro: GSI XII (10~15 µM) blocked the Notch signaling, reduced cell viability and induced apoptosis in MOPC315.BM murine multiple myeloma cells in vitro. GSI XII (10 µM) impaired murine osteoclast differentiation of receptor activator of NF-κB ligand (RANKL)-stimulated RAW264.7 murine monocyte/macrophage cell line [1]. GSI XII (8 μM ~ 15 μM) potently triggered an apoptotic response through inhibition of Notch activity in the breast cancer cells. GSI XII also targets mammary cancer stem-like cells because it dramatically prevented in vitro mammosphere formation [3].
In vivo: Notch inhibition through GSI XII (intraperitoneal injection, 10 mg/kg) reduced myeloma-specific paraprotein levels, bone loss and diminished osteolytic lesions in the MOPC315.BM mice model[1]. Notch inhibition using GSI XII (intraperitoneal injection, 5 mg/kg) blocked embryonal rhabdomyosarcoma tumorigenesis in mice[2].
ex vivo: A model of 3D culture of human breast cancer tissues was developed to study a series of 30 consecutive primary tumors from patients with untreated breast cancer for their sensitivity to the Notch inhibitor GSI XII (15 μM). The results indicated that 24 tumors are sensitive to apoptosis induction by GSIXII.
References:
[1]. Schwarzer R, Nickel N, Godau J, et al. Notch pathway inhibition controls myeloma bone disease in the murine MOPC315. BM model[J]. Blood cancer journal, 2014, 4(6): e217.
[2]. Belyea B C, Naini S, Bentley R C, et al. Inhibition of the Notch-Hey1 axis blocks embryonal rhabdomyosarcoma tumorigenesis[J]. Clinical Cancer Research, 2011, 17(23): 7324-7336.
[3]. Séveno C, Loussouarn D, Bréchet S, et al. γ-Secretase inhibition promotes cell death, Noxa upregulation, and sensitization to BH3 mimetic ABT-737 in human breast cancer cells[J]. Breast Cancer Research, 2012, 14(3): R96.
Cas No. | 161710-10-7 | SDF | |
Synonyms | Z-IL-CHO; GSI-XII; γ-Secretase inhibitor XII | ||
Chemical Name | benzyl ((2R,3R)-3-methyl-1-(((R)-4-methyl-1-oxopentan-2-yl)amino)-1-oxopentan-2-yl)carbamate | ||
Canonical SMILES | O=C(N[C@@H](C(N[C@@H](C=O)CC(C)C)=O)[C@@H](CC)C)OCC1=CC=CC=C1 | ||
Formula | C20H30N2O4 | M.Wt | 362.46 |
Solubility | ≥ 10.8mg/mL in DMSO | Storage | Store at -20°C |
General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. |
Prepare stock solution | |||
1 mg | 5 mg | 10 mg | |
1 mM | 2.7589 mL | 13.7946 mL | 27.5893 mL |
5 mM | 0.5518 mL | 2.7589 mL | 5.5179 mL |
10 mM | 0.2759 mL | 1.3795 mL | 2.7589 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Average Rating: 5
(Based on Reviews and 16 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *